 |
|
Antiretroviral Treatment in Pediatric HIV Infection in the United States
From Clinical Trials to Clinical Practice
Susan Brogly, PhD;
Paige Williams, PhD;
George R. Seage III, ScD;
James M. Oleske, MD, MPH;
Russell Van Dyke, MD;
Kenneth McIntosh, MD; for the PACTG 219C Team
JAMA. 2005;293:2213-2220.
Context Antiretroviral therapy (ART) for pediatric human immunodeficiency virus (HIV) infection has evolved from simple nucleoside reverse transcriptase inhibitor (NRTI) regimens to complex combination therapies based largely on evidence from clinical trials. However, the integration of novel ART into the clinical care of pediatric HIV infection has not been examined.
Objectives To describe changes in the treatment of pediatric HIV infection in the United States from 1987-2003, to assess concordance of initial regimens with US pediatric guidelines, and to identify predictors of the first regimen switch.
Design, Setting, and Participants The study population included 766 perinatally HIV-infected children in the Pediatric AIDS Clinical Trials Group 219C cohort born before January 1, 2004, who had not participated in an ART clinical trial at 219C enrollment or during follow-up.
Main Outcome Measures Proportion of children receiving specific ART regimens, proportion of children initiating ART according to pediatric guidelines, and time to first regimen switch (risk of switching).
Results Single and dual NRTI regimens were used most frequently through 1997. In 1998, 2 years after protease inhibitors were approved for adult HIV infection and at the time pediatric guidelines were issued, regimens of highly active antiretroviral therapy including a protease inhibitor became most frequently used. From 1998-2003, 22% of children initiated ART with a regimen not recommended by pediatric guidelines. In multivariate regression, the risk of switching decreased with age at ART initiation (hazard ratio [HR], 0.96; 95% confidence interval [CI], 0.94-0.99) and increased with year of initiation (HR, 1.28; 95% CI, 1.23-1.33). The risk of switching was higher in children who started with 1 NRTI (HR, 8.05; 95% CI, 5.80-11.18), 2 NRTIs (HR, 4.08; 95% CI, 3.08-5.40), or an unconventional regimen (HR, 6.23; 95% CI, 3.36-11.54) vs children who started with a protease inhibitor–containing regimen; and in children who initiated ART at CD4 T lymphocyte percentages less than 15 vs 15 or greater (HR, 2.90; 95% CI, 1.03-8.13).
Conclusions There was a short lag between the identification of novel ART and its adoption in the pediatric community. A variety of regimens were used, including some unorthodox therapies. Important predictors of first regimen switch were identified.
Author Affiliations: Center for Biostatistics in AIDS Research (Drs Brogly, Williams, and Seage), and Departments of Biostatistics (Drs Brogly and Williams) and Epidemiology (Dr Seage), Harvard School of Public Health, Boston, Mass; Department of Pediatrics, University of Medicine & Dentistry of New Jersey, Newark (Dr Oleske); Department of Pediatrics, Tulane University Health Sciences Center, New Orleans, La (Dr Van Dyke); and Division of Infectious Diseases, Children’s Hospital Boston, Boston, Mass (Dr McIntosh).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Temporal Trends in Early Clinical Manifestations of Perinatal HIV Infection in a Population-Based Cohort
David R. Berk, Meira S. Falkovitz-Halpern, David W. Hill, Catherine Albin, Antonio Arrieta, Jane M. Bork, Deborah Cohan, Bjorn Nilson, Ann Petru, Juan Ruiz, Peggy Sue Weintrub, Wanda Wenman, Yvonne A. Maldonado, and for the California Pediatric HIV Study Group
JAMA. 2005;293(18):2221-2231.
ABSTRACT
| FULL TEXT
Balancing the Upside and Downside of Antiretroviral Therapy in Children
Ram Yogev
JAMA. 2005;293(18):2272-2274.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Incidence of Noninfectious Conditions in Perinatally HIV-Infected Children and Adolescents in The HAART Era
Nachman et al.
Arch Pediatr Adolesc Med 2009;163:164-171.
ABSTRACT
| FULL TEXT
Update on antiretroviral therapy
Riordan and Bugembe
Arch. Dis. Child. 2009;94:70-74.
ABSTRACT
| FULL TEXT
Association of Site-specific and Participant-specific Factors with Retention of Children in a Long-term Pediatric HIV Cohort Study
Williams et al.
Am J Epidemiol 2008;167:1375-1386.
ABSTRACT
| FULL TEXT
Predictors of Adherence to Antiretroviral Medications in Children and Adolescents With HIV Infection
Williams et al.
Pediatrics 2006;118:e1745-e1757.
ABSTRACT
| FULL TEXT
Incidence of opportunistic and other infections in HIV-infected children in the HAART era.
Gona et al.
JAMA 2006;296:292-300.
ABSTRACT
| FULL TEXT
Long-term Experience With Combination Antiretroviral Therapy That Contains Nelfinavir for up to 7 Years in a Pediatric Cohort
Scherpbier et al.
Pediatrics 2006;117:e528-e536.
ABSTRACT
| FULL TEXT
Trends in Pediatric HIV Treatment, 1987-2003
AIDS Clin Care 2005;2005:3-3.
FULL TEXT
Progress in Treatment of Pediatric HIV Infection
JWatch Infect. Diseases 2005;2005:2-2.
FULL TEXT
Balancing the Upside and Downside of Antiretroviral Therapy in Children
Yogev
JAMA 2005;293:2272-2274.
FULL TEXT
|
